# Immunocore

可溶性 gp100 TCR-抗 CD3 双特异性 Kimmtrak（tebentafusp）用于 HLA-A02:01+ 转移性葡萄膜黑色素瘤，2026 年 4 月数据显示可将五年存活率提高一倍——首个获批的 TCR 双特异性。

Source: https://cn.bioecon.ru/companies/immunocore/
Updated: 2026-07-11

- 国家: United Kingdom
- 代码: IMCR

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 截至2025年末现金及现金等价物$864 million | https://www.immunocore.com/investors/financials-filings/annual-reports/content/0001140361-26-015125/0001140361-26-015125.pdf |
| 产能 | 外包给第三方委托生产机构（CMO）；公司不拥有也不计划建设自有生产产能 | https://www.nullexposure.com/suppliers/imcr |
| 生产基地 | 丹麦、德国和荷兰（最终包装） | https://www.immunocore.com/investors/financials-filings/sec-filings/content/0001671927-26-000005/0001671927-26-000005.pdf, https://www.nullexposure.com/suppliers/imcr |
| 员工人数 | 截至2025年12月31日为524名全职员工 | https://longbridge.com/en/news/276883036.md |
| 营收 | 2025财年净营收$4亿 | https://www.immunocore.com/investors/financials-filings/annual-reports/content/0001140361-26-015125/0001140361-26-015125.pdf |
| 营收 | 2026年第一季度净产品营收$106.7 million | https://www.immunocore.com/investors/news/press-releases/detail/130/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update |
| 监管批准 | KIMMTRAK已在包括美国、欧盟、英国、加拿大和澳大利亚在内的39个国家获批用于转移性葡萄膜黑色素瘤 | https://www.immunocore.com/investors/financials-filings/sec-filings/content/0001671927-26-000009/0001671927-26-000009.pdf, https://www.immunocore.com/investors/news/press-releases/detail/34/the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-australian-therapeutic-goods-administration-tga-and-health-canada-approve-kimmtrak-tebentafusp-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma |

独立来源: longbridge.com, nullexposure.com

## 技术

- [TCR 疗法（T 细胞受体工程化 T 细胞）](https://cn.bioecon.ru/technology/tcr-therapy/)